Targeted Solutions for Viral Diseases

Novel antiviral therapeutics for the treatment of serious and/or chronic viral diseases including hepatitis C, influenza and norovirus.

View Product Pipeline

About Us

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.

Learn More

Technology

We utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.

Learn More

Development Programs

Our development programs include a wide variety of serious and/or chronic viral diseases including hepatitis C, influenza and norovirus.

Learn More
Program Discovery Preclinical Phase 1 Phase 2 Phase 3
Hepatitis C CC-31244
(Pan-genotypic NS5B NNI)
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Hepatitis C CC-2850
(Pan-genotypic NS5B Nuc)
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Hepatitis C CC-2069
(Pan-genotypic NS5A inhibitor)
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Influenza CC-42344
(Influenza A PB2 Inhibitor)
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Influenza Influenza A/B Inhibitor
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Norovirus Noro Polymerase Inhibitor
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

Investor Presentation

View our latest Corporate Presentation

View Presentation